Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391115 · ClinicalTrials.gov registry record
Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 38
- Enrollment target
NCT03391115: Completed study, sponsored by University of Colorado, Denver.
NCT03391115 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03391115 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of this research is to develop patient-centered palliative care interventions to improve patient-provider communication and Quality of Life (QoL) of ethnic and racial minority patients living with life-limiting illnesses. Eliciting personal experiences is an effective way for patients to communicate their cultural values and beliefs. This study will assess how to integrate the patients' personal experience narratives into the electronic health record (EHR). The primary hypothesis is that the implementation of a patient-centered intervention to elicit personal experiences that are included in the EHR will improve patient-provider communication and patients' QoL.
Primary Outcome
Using an observational design, this measure (exit interviews) were completed with 20 inpatient participants and 18 nurse participants. The qualitative data from the interviews were used to define and refine the storytelling intervention. The data collected from the exit interview is qualitative in nature and therefore does not have a numerical value.
Interventions
- BEHAVIORAL Storytelling Intervention for Patient Participants
- BEHAVIORAL Storytelling Intervention for Nurse Participants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2018-11-30 |
What the finished NCT03391115 record still lists
NCT03391115 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Storytelling Intervention for Patient Participants is the first listed.
NCT03391115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03391115 about?
NCT03391115 is a clinical study titled "Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness". The purpose of this research is to develop patient-centered palliative care interventions to improve patient-provider communication and Quality of Life (QoL) of ethnic and racial minority patients living with life-limiting illnesses. Eliciting personal experiences is an effective way for patients to...
What is the current status of trial NCT03391115?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2017-11-15. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03391115?
The interventions under investigation include: Storytelling Intervention for Patient Participants (BEHAVIORAL), Storytelling Intervention for Nurse Participants (BEHAVIORAL).
Who is sponsoring clinical trial NCT03391115?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI